Navigation Links
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
Date:6/8/2009

at involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for Zerenex and KRX-0401; our ability to meet anticipated development timelines for Zerenex and KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
    Lauren Fischer
    Director, Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5962
    E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... King of Prussia, PA (PRWEB) May 21, 2015 ... that Julia O’Neill has joined the firm as senior ... more than 30 years of experience in the management ... the vaccines, biologics, pharmaceutical and chemical industries. , “We’re ... enhance our longstanding capabilities in data analytics,” said Dr. ...
(Date:5/20/2015)... , May 20, 2015  Select Medical ... the Federal Trade Commission granted early termination of ... Improvements Act of 1976, as amended, applicable to ... Acquisition Corporation, a joint venture that Select has ... As previously announced, MJ Acquisition Corporation ...
(Date:5/20/2015)... , May 20, 2015  Haemonetics Corporation (NYSE: ... President & CEO, will present at The Jefferies 2015 ... on June 1 st , 2015 at 8:30am ... Mr. Concannon,s presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Diana Davis, PhD, Aiguo Zhang, PhD, Chloe Etienne, Ivan Huang,and Michele Malit, Bio-Rad ... , Introduction ... multiplex sandwich immunoassays. , The concentrations of ... quantitated using a calibration or standard curve. More specifically, , ...
... Maria C Jenmalm, 1 Michele Malit, 2 Jim Torrence, 2 , ... 1 Department of Molecular and Clinical Medicine, Division of Paediatrics, , ... Nobel Drive, Hercules, CA 94547 USA , ... Cytokines play a significant role in hematopoiesis, inflammation, and , ...
... , Matthew W. Fields, Section of Microbiology, Cornell ... Introduction , ... organisms by quantitating mRNA levels. The relative abundance of mRNA ... blots, but these , methods depend on accurate ...
Cached Biology Technology:Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 2Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 3Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 4Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 5Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 6Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 7Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 8Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A 2Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A 3Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A 4Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A 5Quantitation of RNA for Hybridization Blots Using the VersaFluor Fluorometer 2
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... Since its inception in 2009, the " Contributions to the ... ZooKeys has been playing an important role in ... North America. With a total of 49 publications by 38 ... publications such as Canadian Staphylinidae. Geographic coverage in ...
... University of Granada researchers have designed a guideline for physicians ... disease that makes the subject develop reverse sex, which occurs ... genes. AIS has low prevalence (it only affects one ... of tissues to respond to the action of male hormones. ...
... GSA Bulletin papers published online 11 Jan. 2013 include ... UK, and New Zealand. Multiple locations in the western U.S. ... Guatemala. Papers cover , 1. Holocene record of ... salt, and the fossil forests of Joggins Fossil Cliffs UNESCO ...
Cached Biology News:ZooKeys opens the gates to America's moth diversity 2Study of a rare disease making people look like a woman but having male genitals under study 2GSA Bulletin starts 2013 with 13 new papers published online ahead of print 2GSA Bulletin starts 2013 with 13 new papers published online ahead of print 3GSA Bulletin starts 2013 with 13 new papers published online ahead of print 4GSA Bulletin starts 2013 with 13 new papers published online ahead of print 5GSA Bulletin starts 2013 with 13 new papers published online ahead of print 6GSA Bulletin starts 2013 with 13 new papers published online ahead of print 7GSA Bulletin starts 2013 with 13 new papers published online ahead of print 8GSA Bulletin starts 2013 with 13 new papers published online ahead of print 9GSA Bulletin starts 2013 with 13 new papers published online ahead of print 10GSA Bulletin starts 2013 with 13 new papers published online ahead of print 11
Request Info...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml ... , 0.2 ml BLT5615 glycerol stock , 1010 ... Negative Control Lysate , 50 l S-protein HRP Conjugate ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
...
Biology Products: